Tensions show no sign of easing ahead of President Xi Jinping’s upcoming meeting with Obama
Time has run out for Procter & Gamble's CEO as the company turns to a famed management star
Washington is pressing China to stop its cyber attacks. Beijing's response: Look who's talking
SundaySky generates individualized, up-to-the-minute billing videos for AT&T and other companies
Net flow into debt hedge funds is the highest since 2007
Roel Vertegaal's PaperTab is like an iPad you can fold, spindle, or mutilate
Networks are staggering première dates to capture viewers and ad dollars
Jim Dean, the dean of UNC's Kenan-Flagler School, calls it quits for a more lofty title: provost
Rob Rhinehart is living on a substance he engineered to replace food, and he just raised more than $200,000 through crowdfunding to manufacture it
Founder: Dr. John Hadden
VC Investment over the last four quarters: $25 million
IRX Therapeutics is a 40-employee biotech firm developing drugs to restore immune system function, particularly in patients with head and neck cancer. Founded over a decade ago and backed by more than $60 million raised mostly from high-net-worth individuals, the company has reduced headcount by a third and delayed some clinical trials planned for 2009, according to Chief Financial Officer Jeffrey Hwang.
Key to startup success: "In normal times where the capital is available, the difference maker among people with good ideas is sharp execution. There's never a substitute for the ability to attract and retain experienced, qualified people to take advantage of the discovery you've made."